Gideon Hirschfield & Or Steg Saban

Orlee Guttman

• STC Opening Remarks     
• The biologic mechanisms and pathophysiology of cholestasis
• Adult presentations of "pediatric" genetic cholestatic diseases - Silvia Vilarinho 
• Ductal plate malformations and ciliopathies: a primer for all! - Jessica Wen
• New and emerging therapies in cholestatic liver disease - Richard Thompson
• Round Table & Q&A

• Primer on primary biliary cholangitis: biology and presentation - Hin Hin Ko
• New therapies for primary biliary cholangitis - Gideon Hirschfield
• Primary sclerosing cholangitis: where do we stand in the adult world - Kristel Leung
• Unique pediatric aspects in primary sclerosing cholangitis
• Autoimmune hepatitis: what treatment gaps remain? - Aldo Montano Loza
• Q&A

• "Overlap" syndromes: real or imaginary?
• Steroid minimization in childhood autoimmune liver disease - Or Steg Saban
• Microbiome manipulation and GI-Liver disease - Richard Kellermayer
• Treatment and management options in intrahepatic cholestasis of pregnancy - Saumya Jayakumar
• Transition of hepatology patients from pediatric to adult care - Susan Gilmour 
• Q&A

• Cystic fibrosis liver disease in the era of Trikafta - Michael Narkewicz
• Alpha-1 antitrypsin deficiency: will molecular therapy change outcomes?
• Hepatitis Delta: entering a new era - Carla Coffin
• IgG4 disease: from the lens of Rheumatology to the GI
• Biliary atresia: etiology and treatment
• Q&A

Opening Remarks
Liver Forum Session 1 - MELD and MELD Alternatives

• The Case for Change: Where MELD Fails
• Alternative Models for Organ Allocation: International and Canadian Perspectives
• Panel Discussion Q&A

Liver Forum Session 2 - Immunosuppression in Liver Transplantation

• To Induce or Not to Induce: Evolving Practices in 2025
• Maintenance Strategies: Balancing Efficacy and Toxicity
• Diagnosis and Management of Antibody-Mediated Rejection in Liver Transplantation
• Panel Discussion Q&A

Liver Forum Session 3 - Expanding the Donor Pool 

• NRP in DCD: The Canadian Experience and Ethical Frameworks
• Ex-vivo Liver Perfusion: Clinical Experience and Research Priorities
• How Should Canada Adopt and Scale These Technologies? - Panel Discussion